The effectiveness and value of emicizumab and valoctocogene roxaparvovec for the management of hemophilia A without inhibitors

被引：8
|
作者：
Agboola, Foluso [1 ]
Rind, David M. [1 ]
Walton, Surrey M. [2 ]
Herron-Smith, Serina [1 ]
Quach, Danny [2 ]
Pearson, Steven D. [1 ]
机构：
[1] Inst Clin & Econ Review, Boston, MA 02109 USA
[2] Univ Illinois, Ctr Pharmacoepidemiol & Pharmacoecon Res, Chicago, IL USA
来源：
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY | 2021年 / 27卷 / 05期
关键词：
RECOMBINANT FACTOR-VIII;
D O I：
10.18553/jmcp.2021.27.5.667
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：667 / 673
页数：7
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS ANALYSIS OF RFVIIIFC, PEGYLATED RFVIII, AND EMICIZUMAB FOR THE PROPHYLACTIC TREATMENT OF SEVERE HEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN THE UNITED STATES
    Li, N.
    Bullement, A.
    McMordie, S.
    Hatswell, A. J.
    Wilson, K.
    VALUE IN HEALTH, 2019, 22 : S389 - S389
  • [42] Post-Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients with Congenital Hemophilia A with Inhibitors
    Shima, Midori
    Fukutake, Katsuyuki
    Matsumoto, Masanori
    Sugimura, Yoshihiko
    Sugita, Chiaki
    Ji, Lyu
    Kawano, Mika
    Matsushita, Tadashi
    BLOOD, 2024, 144 : 2583 - 2584
  • [43] Real-World Outcomes of Emicizumab in Hemophilia A with or without FVIII Inhibitors from the Canadian Hemophilia Bleeding Disorder Registry
    Poon, Man-Chiu
    Lee, Adrienne
    Germini, Federico
    Keepanasseril, Arun
    Ibrahim, Quazi
    Nissen, Francis
    Moreno, Katya
    Santos, Michelle
    Iserman, Emma
    Matino, Davide
    Iorio, Alfonso
    BLOOD, 2022, 140 : 8465 - 8467
  • [44] A literature review of major surgery experience with emicizumab in people with hemophilia A without factor VIII inhibitors
    Castaman, Giancarlo
    Croteau, Stacy E.
    Quon, Doris
    Lee, Lucy
    Polito, Letizia
    Jimenez-Yuste, Victor
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2025, 9 (01)
  • [45] Assessment of the impact of pharmaceutical consultations at initiation of a treatment with emicizumab in patients with severe hemophilia A without inhibitors
    Allah, M. Nasr
    Pieragostini, R.
    Oka, G.
    Batista, R.
    Stieltjes, N.
    Lopez, I.
    ANNALES PHARMACEUTIQUES FRANCAISES, 2022, 80 (06): : 915 - 922
  • [46] Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A single-center report
    Warren, Beth Boulden
    Chan, Adrian
    Branchford, Brian R.
    Buckner, Tyler W.
    Moyer, Genevieve
    Gibson, Elizabeth
    Thornhill, Dianne
    Wang, Michael
    Ng, Christopher J.
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2021, 5 (05)
  • [47] IMPACT OF SWITCHING PROPHYLAXIS TREATMENT FROM FACTOR VIII TO EMICIZUMAB IN HEMOPHILIA A PATIENTS WITHOUT INHIBITORS
    Escobar, Miguel
    Agrawal, Neha
    Chatterjee, Sagnik
    Bhattacharya, Swastik
    Caicedo, Jorge
    Bullano, Michael
    Schultz, Robert G.
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : E34 - E34
  • [48] RESOURCE CONSUMPTION ANALYSIS IN PATIENTS WITH HEMOPHILIA A WITHOUT INHIBITORS ON PROPHYLAXIS WITH FVIII BEFORE SWITCHING TO EMICIZUMAB
    Giacomini, E.
    Leogrande, M.
    Motta, L.
    Tempre, R.
    Bendinelli, S.
    Degli Esposti, L.
    VALUE IN HEALTH, 2023, 26 (12) : S69 - S69
  • [49] Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors
    Escobar, Miguel
    Agrawal, Neha
    Chatterjee, Sagnik
    Bhattacharya, Swastik
    Caicedo, Jorge
    Bullano, Michael
    Schultz, Bob G. G.
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 574 - 580
  • [50] Real-world experience of emicizumab prophylaxis in Korean children with severe hemophilia A without inhibitors
    Kim, Sung Eun
    Kim, Ji Yoon
    Park, Jeong A.
    Lyu, Chuhl Joo
    Hahn, Seung Min
    Han, Jung Woo
    Park, Young Shil
    BLOOD RESEARCH, 2024, 59 (01)
12345